AuthorMouseDoctor

Control of Fatigue a Placebo effect?

A cross-over trial of 3 different fatigue drugs showed no difference from the fake treatment. Maybe ProfG wil comment on this, but it shows why trials are done Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue...

If you want to get rid of EBV maybe time to look at CAR-T

This is one for the hard-core scientisty types, but you ask about how to get rid of EBV. Here is a type of vaccination. You engineer T cells tonget rid of EBV. This is a mouse study but the CAR-T technology can and has been used in humans CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.Slabik C, Kalbarczyk M...

Not being treated is a risk factor for secondary progressive MS

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaresi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi...

ProfK launched ChariotMS last week. Case reports of COVID-cladribine

There has not been as much information about COVID-19 and oral cladribine as has occurred with anti-CD20. In view of the launch of ChariotMS by ProfK. This case report is welcome news in that both people who developed COVID were not hosptialised and recovered. They were relatively young and may be expected to recover but the fact that they had COVID shortly after treatment when the depleting...

#MSCOVID19 Viral Vaccines

We have heard about the RNA vaccines and today MEDCRAM (118) will tell you about the Oxford/Astrazeneca Vaccine. This is the vaccine that the UK has purchased the most of. I think it is unlikely that it will be offered to people on immunosuppressive DMT, although it is replication deficient and so should not be able to cause an infection. This week we had a nice email from Dr Seheult “Dear...

#MSCOVID19 Antibodies

casirivimab and imdevimab, bamlanivimab If you live in the USA the FDA has given emergency approval for two antibodies (one a cocktail of two antibodies 1.2g cashirivimab and imdevimab 1.2g) and the other a single 0.7g antibody (Bamlanivimab) available for the old age people likely to become severe to reduce the chance of hospitalization. It is not approved for severely affected people who are...

#MSCOVID19 Viral vaccines

I got a good kicking for for talking about an MS drug that we know is inferior to the big guns (High efficacy DMT), when the little guns (Lower efficacy DMT) is all that is offered. As I said, a little gun is better than no guns (OK bad analogy as Guns are bad! We should not have them and I am sure the National Rifle Association will be after me for this…yep I know many of our US readers...

When Fat is Useful: COVID-19 vaccine readiness and ocrelizumab

As you may know we have been publishing the trial results of ocrelizumab studies. The problem is that we write them in a style and manner that we chose and this may not be what pharma wants to say. This gives them an incentive to report the study before we say anything. If the information is out there in a readily searchable form (i.e a paper) then we have no incentive to report it. But if we say...

HSCT and COVID-19 Mexican Style

I know there is great interest in HSCT and I also know any posts on HSCT is like catnip to the zealots. So I can’t be bothered to engage or defend as no matter what one says it is going to be wrong if is says something that people don’t want to hear. Removing your immune system puts you at serious risk from infection. Once you immune systme regenerates the risk goes away. This is...

Translate

Categories

Recent Posts

Recent Comments

Archives